RCI
KPTI icon

Ridgeback Capital Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Ridgeback Capital Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-263,013
Closed -$37M – 1
2018
Q4 		$37M Buy
+263,013
New +$44.4M 100% 1

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Ridgeback Capital Investments's KPTI Position: Q1 2019 in Review

Ridgeback Capital Investments sold out of Karyopharm Therapeutics (KPTI) in Q1 2019, closing a stake of 263,013 shares — an estimated $37M sold.

Ridgeback Capital Investments first reported a position in KPTI in Q4 2018 and held it in 1 quarter. The position peaked at $37M in Q4 2018. 108 funds tracked by Wall St. Rank hold KPTI as of Q1 2019.

  • Ridgeback Capital Investments reported no remaining Karyopharm Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Ridgeback Capital Investments sold 263,013 Karyopharm Therapeutics shares in Q1 2019, an estimated $37M.
  • Ridgeback Capital Investments first reported a position in Karyopharm Therapeutics in Q4 2018 and held it in 1 quarter.
  • Ridgeback Capital Investments's Karyopharm Therapeutics position peaked at $37M in Q4 2018.
  • 108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2019.

Based on Ridgeback Capital Investments's 13F filing for Q1 2019.